“RECENT UPDATE ON PYRIMIDINE DERIVATIVES AS POTENTIAL DPP-IV INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS”, Journal of Pharmaceutical Negative Results, pp. 5734–5743, Dec. 2022, doi: 10.47750/pnr.2022.13.S07.696.